Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Cardiology Division, Massachusetts General Hospital, and Cardiometabolic Trials, Baim Institute for Clinical Research, Boston, MA.
Diabetes Care. 2022 Jul 7;45(7):1670-1690. doi: 10.2337/dci22-0014.
Heart failure (HF) has been recognized as a common complication of diabetes, with a prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data also suggest that HF may develop in individuals with diabetes even in the absence of hypertension, coronary heart disease, or valvular heart disease and, as such, represents a major cardiovascular complication in this vulnerable population; HF may also be the first presentation of cardiovascular disease in many individuals with diabetes. Given that during the past decade, the prevalence of diabetes (particularly type 2 diabetes) has risen by 30% globally (with prevalence expected to increase further), the burden of HF on the health care system will continue to rise. The scope of this American Diabetes Association consensus report with designated representation from the American College of Cardiology is to provide clear guidance to practitioners on the best approaches for screening and diagnosing HF in individuals with diabetes or prediabetes, with the goal to ensure access to optimal, evidence-based management for all and to mitigate the risks of serious complications, leveraging prior policy statements by the American College of Cardiology and American Heart Association.
心力衰竭(HF)已被认为是糖尿病的一种常见并发症,在糖尿病患者中的患病率高达 22%,且发病率不断上升。数据还表明,即使在没有高血压、冠心病或心脏瓣膜病的情况下,糖尿病患者也可能发生心力衰竭,因此,心力衰竭是这一脆弱人群的主要心血管并发症;心力衰竭也可能是许多糖尿病患者心血管疾病的首发表现。鉴于在过去十年中,全球糖尿病(尤其是 2 型糖尿病)的患病率上升了 30%(预计患病率还将进一步上升),心力衰竭给医疗保健系统带来的负担将继续增加。美国糖尿病协会共识报告的范围,指定了来自美国心脏病学会的代表,旨在为从业者提供有关在糖尿病或糖尿病前期患者中筛查和诊断心力衰竭的最佳方法的明确指导,目标是确保所有患者都能获得最佳的、基于证据的管理,并减轻严重并发症的风险,利用美国心脏病学会和美国心脏协会之前的政策声明。